SCI Pharmtech Inc (TW:4119) — Market Cap & Net Worth
Market Cap & Net Worth: SCI Pharmtech Inc (4119)
SCI Pharmtech Inc (TW:4119) has a market capitalization of $158.51 Million (NT$5.03 Billion) as of June 17, 2026. Listed on the TW stock exchange, this Taiwan-based company holds position #17541 globally and #909 in its home market, demonstrating a 2.43% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SCI Pharmtech Inc's stock price NT$42.10 by its total outstanding shares 119508634 (119.51 Million). Review 4119 liabilities breakdown to assess the company's total debt and financial obligations.
SCI Pharmtech Inc Market Cap History: 2015 to 2026
SCI Pharmtech Inc's market capitalization history from 2015 to 2026. Data shows change from $295.31 Million to $158.51 Million (-4.20% CAGR).
SCI Pharmtech Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SCI Pharmtech Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.14x
SCI Pharmtech Inc's market cap is 0.14 times its annual revenue
Latest Price to Earnings (P/E) Ratio
1.71x
SCI Pharmtech Inc's market cap is 1.71 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $250.50 Million | $1.90 Billion | $416.95 Million | 0.13x | 0.60x |
| 2017 | $197.39 Million | $1.30 Billion | $190.98 Million | 0.15x | 1.03x |
| 2018 | $248.43 Million | $1.94 Billion | $447.24 Million | 0.13x | 0.56x |
| 2019 | $394.43 Million | $2.36 Billion | $571.10 Million | 0.17x | 0.69x |
| 2020 | $314.07 Million | $2.69 Billion | $360.12 Million | 0.12x | 0.87x |
| 2021 | $315.59 Million | $864.22 Million | $55.70 Million | 0.37x | 5.67x |
| 2022 | $366.31 Million | $899.74 Million | $308.78 Million | 0.41x | 1.19x |
| 2023 | $364.47 Million | $1.20 Billion | $294.72 Million | 0.30x | 1.24x |
| 2024 | $341.13 Million | $1.52 Billion | $534.68 Million | 0.22x | 0.64x |
| 2025 | $183.36 Million | $1.34 Billion | $107.37 Million | 0.14x | 1.71x |
Competitor Companies of 4119 by Market Capitalization
Companies near SCI Pharmtech Inc in the global market cap rankings as of June 17, 2026.
Key companies related to SCI Pharmtech Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
SCI Pharmtech Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, SCI Pharmtech Inc's market cap moved from $295.31 Million to $ 158.51 Million, with a yearly change of -4.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$158.51 Million | -13.55% |
| 2025 | NT$183.36 Million | -46.25% |
| 2024 | NT$341.13 Million | -6.40% |
| 2023 | NT$364.47 Million | -0.50% |
| 2022 | NT$366.31 Million | +16.07% |
| 2021 | NT$315.59 Million | +0.48% |
| 2020 | NT$314.07 Million | -20.37% |
| 2019 | NT$394.43 Million | +58.77% |
| 2018 | NT$248.43 Million | +25.86% |
| 2017 | NT$197.39 Million | -21.20% |
| 2016 | NT$250.50 Million | -15.18% |
| 2015 | NT$295.31 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of SCI Pharmtech Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $158.51 Million USD |
| MoneyControl | $158.51 Million USD |
| MarketWatch | $158.51 Million USD |
| marketcap.company | $158.51 Million USD |
| Reuters | $158.51 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SCI Pharmtech Inc
SCI Pharmtech, Inc. engages in the research and development, manufacture, and sale of active pharmaceutical ingredients, intermediates, and specialty chemicals. The company offers active pharmaceutical ingredients, including adenine, articaine HCl, atomoxetine HCl, bisoprolol hemifumarate, brinzolamide, buprenorphine and buprenorphine HCl, cannabidol, divalproex sodium, duloxetine HCl, hydroxychl… Read more